{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:03:30Z","timestamp":1789639410262,"version":"4.0.0"},"reference-count":163,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Mark. Access Health Policy","JMAHP"],"abstract":"<jats:p>The Regulation (EU) 2021\/2282 on health technology assessment (HTAR) harmonises clinical evidence assessment across Europe. However, national appraisal, pricing, and reimbursement processes remain divergent and could affect the efficiency of decision-making and patient access. Here we mapped the sequencing of national assessment, pricing, and reimbursement steps across 30 European countries. National pathways from marketing authorisation to reimbursed access were systematically identified and coded as categorical process sequences. Inpatient and outpatient pathways were analysed separately. Pathway dissimilarities were calculated using Optimal Matching and grouped by hierarchical clustering. We further explored whether clusters differed with regard to country-level indicators, including medicine availability, average time to access, gross domestic product, and healthcare expenditure. We found substantial procedural heterogeneity across countries in both inpatient and outpatient settings. Nevertheless, recurring pathway structures were identified. Across settings, the dominant distinction was between assessment-led pathways, in which evidence assessment precedes pricing and reimbursement steps, and pricing-led pathways, in which price formation occurs prior to assessment and reimbursement-related steps. Cluster membership was not associated with any country-level indicators. Our findings provide policymakers, agencies, and industry with a baseline for understanding national procedural heterogeneity and for evaluating how market access pathways evolve as the JCA is implemented.<\/jats:p>","DOI":"10.3390\/jmahp14030055","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:17Z","timestamp":1789632197000},"page":"55","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Post-Authorisation Maze: Mapping of European Pharmaceutical Market Access Pathways in the Early JCA Era"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7256-1363","authenticated-orcid":false,"given":"Lisa-Maria","family":"Hagemann","sequence":"first","affiliation":[{"name":"<i>AMS<\/i> Advanced Medical Services GmbH, 80639 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-7538","authenticated-orcid":false,"given":"Karolin","family":"Eberle","sequence":"additional","affiliation":[{"name":"<i>AMS<\/i> Advanced Medical Services GmbH, 80639 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Maurer","sequence":"additional","affiliation":[{"name":"<i>AMS<\/i> Advanced Medical Services GmbH, 80639 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Carls","sequence":"additional","affiliation":[{"name":"<i>AMS<\/i> Advanced Medical Services GmbH, 80639 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas D.","family":"Meid","sequence":"additional","affiliation":[{"name":"<i>AMS<\/i> Advanced Medical Services GmbH, 80639 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6745-964X","authenticated-orcid":false,"given":"Eva-Maria","family":"Reuter","sequence":"additional","affiliation":[{"name":"<i>AMS<\/i> Advanced Medical Services GmbH, 80639 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","unstructured":"IQVIA (2026, July 15). EFPIA Patients W.A.I.T. Indicator 2025 Survey. Available online: https:\/\/www.efpia.eu\/media\/mnfdwzax\/efpia-patients-wait-indicator-2025.pdf."},{"key":"ref_2","unstructured":"The European Parliament and the Council of the European Union (2026, July 15). Regulation (EU) 2021\/2282 of The European Parliament and of the Council of 15 December 2021 on Health Technology Assessment and Amending Directive 2011\/24\/EU. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32021R2282."},{"key":"ref_3","unstructured":"European Commission (2026, July 15). Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions. Pharmaceutical Strategy for Europe, Document 52020DC0761. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:52020DC0761."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12961-015-0028-5","article-title":"From market access to patient access: Overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries","volume":"13","author":"Panteli","year":"2015","journal-title":"Health Res. Policy Syst."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s41669-021-00311-5","article-title":"Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries","volume":"6","author":"Fontrier","year":"2022","journal-title":"PharmacoEconomics-Open"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mela, A., Rdzanek, E., Jaroszy\u0144ski, J., Furtak-Niczyporuk, M., Jab\u0142o\u0144ski, M., and Niewada, M. (2023). Reimbursement decision-making system in Poland systematically compared to other countries. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1153680"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jval.2016.08.725","article-title":"Variation in Health Technology Assessment and Reimbursement Processes in Europe","volume":"20","author":"Akehurst","year":"2017","journal-title":"Value Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pharp.2026.06.007","article-title":"Comparative review of selected health technology assessment agencies: Features and insights for health technology assessment development and improvement","volume":"2","author":"Dai","year":"2026","journal-title":"Pharmacoecon. Policy"},{"key":"ref_9","unstructured":"Italian Medicines Agency (2026, July 31). Scientific and Economic Committee for Medicines. Italian Medicines Agency [Internet], Available online: https:\/\/www.aifa.gov.it\/en\/web\/guest\/commissione-scientifica-economica."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.gaceta.2019.02.009","article-title":"Evaluation of new medicines in Spain and comparison with other European countries","volume":"34","author":"Epstein","year":"2020","journal-title":"Gac. Sanit."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Jakubowski, S., Holko, P., Nowak, R., Warmuth, M., Dooms, M., Salminen, O., Cortial, L., Selke, G.W., Georgi, C., and Magn\u00fasson, E. (2024). Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1498386"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12687-026-00860-4","article-title":"The impacts of pricing and reimbursement policies on access to cell and gene therapies across Europe","volume":"17","author":"Han","year":"2026","journal-title":"J. Community Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ijc.34753","article-title":"Differences in time to patient access to innovative cancer medicines in six European countries","volume":"154","author":"Vancoppenolle","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.healthpol.2012.09.012","article-title":"Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions","volume":"108","author":"Nicod","year":"2012","journal-title":"Health Policy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10198-016-0823-0","article-title":"Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries","volume":"18","author":"Nicod","year":"2017","journal-title":"Eur. J. Health Econ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13561-018-0201-y","article-title":"Leveraging EUnetHTA\u2019s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer\u2019s point of view","volume":"8","author":"Giuliani","year":"2018","journal-title":"Health Econ. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"105810","DOI":"10.1016\/j.esmoop.2025.105810","article-title":"Access to novel cancer medicines in Europe: Inequities across countries and their drivers","volume":"10","author":"Hofmarcher","year":"2025","journal-title":"ESMO Open"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rogowski, W.H., Hartz, S.C., and John, J.H. (2008). Clearing up the hazy road from bench to bedside: A framework for integrating the fourth hurdle into translational medicine. BMC Health Serv. Res., 8.","DOI":"10.1186\/1472-6963-8-194"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.healthpol.2013.09.007","article-title":"Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems","volume":"113","author":"Allen","year":"2013","journal-title":"Health Policy"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Allen, N., Liberti, L., Walker, S.R., and Salek, S. (2017). A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00384"},{"key":"ref_21","first-page":"78","article-title":"Modern approaches to typologization and modeling in the health technology assessment","volume":"5","author":"Babenko","year":"2024","journal-title":"Sci. Pharm. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10198-017-0871-0","article-title":"Using health technology assessment to assess the value of new medicines: Results of a systematic review and expert consultation across eight European countries","volume":"19","author":"Angelis","year":"2018","journal-title":"Eur. J. Health Econ."},{"key":"ref_23","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA) (2026, July 15). The Root Causes of Unavailability of Innovative Medicines and Delay in Access: Shortening the Wait. Available online: https:\/\/www.efpia.eu\/media\/f5dmk1ti\/efpia-cra-22root-causes-of-unavailability-and-delay22.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Eberle, K., Hagemann, L.M., Schweitzer, M.K., Justl, M., Maurer, J., Carls, A., and Reuter, E.-M. (2025). The PICO Puzzle: Can Public Data Predict EU HTA Expectations for All EU Countries?. J. Mark. Access Health Policy, 13.","DOI":"10.3390\/jmahp13030032"},{"key":"ref_25","unstructured":"(2026, July 15). Pharmaceutical Pricing and Reimbursement Information (PPRI). PPRI Profiles\/Briefs. Available online: https:\/\/ppri.goeg.at\/PPRI_Pharma_Profiles."},{"key":"ref_26","unstructured":"World Health Organization (WHO) (2026, July 15). HTA Country\/Area Profiles. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/health-economics\/hta-country-profiles-2020-21\/hta_updated_merged_final.pdf?sfvrsn=75ac91f6_5."},{"key":"ref_27","unstructured":"Castle, G. (2026, July 15). Pricing & Reimbursement Laws and Regulations 2025: Global Legal Group. Available online: https:\/\/www.globallegalinsights.com\/practice-areas\/pricing-reimbursement-laws-and-regulations\/."},{"key":"ref_28","unstructured":"European Observatory on Health Systems and Policies (2026, July 15). Cyprus: Health System Review 2024. Available online: https:\/\/eurohealthobservatory.who.int\/publications\/i\/cyprus-health-system-review-2024."},{"key":"ref_29","first-page":"1","article-title":"Health Care Reform in Greece: Progress and Reform Priorities","volume":"2021","author":"Jin","year":"2021","journal-title":"IMF Work. Pap."},{"key":"ref_30","unstructured":"Theiss, W. (2026, July 15). Pricing and Reimbursement of Medicinal Products in CEE & SEE. Available online: https:\/\/www.wolftheiss.com\/wp-content\/uploads\/2023\/04\/Life-Science-Guide-2023.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1017\/S0266462324000485","article-title":"Health technology assessment of medicinal products in Greece: A 5-year (2018\u20132023) review of timelines and productivity","volume":"40","author":"Chantzaras","year":"2024","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100095","DOI":"10.1016\/j.hpopen.2023.100095","article-title":"A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes","volume":"4","author":"Abraham","year":"2023","journal-title":"Health Policy OPEN"},{"key":"ref_33","first-page":"639","article-title":"Pharmaceutical regulation and policies in Austria","volume":"13","author":"Vogler","year":"2022","journal-title":"J. Hosp. Pharm. Health Serv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3897\/pharmacia.71.e131159","article-title":"A comparative analysis of pricing and reimbursement systems between Italy and Bulgaria","volume":"71","author":"Cannavale","year":"2024","journal-title":"Pharmacia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"104279","DOI":"10.1016\/j.lpm.2025.104279","article-title":"French reimbursement of health technologies: Assessment is at the heart of the procedure","volume":"54","author":"Carbonneil","year":"2025","journal-title":"La Presse M\u00e9dicale"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s41669-019-00177-8","article-title":"Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines","volume":"4","author":"Connolly","year":"2020","journal-title":"PharmacoEconomics-Open"},{"key":"ref_37","unstructured":"(2026, September 08). \u00d6sterreichische Sozialversicherung. Startseite. Available online: https:\/\/www.sozialversicherung.at."},{"key":"ref_38","unstructured":"\u00d6sterreichische Sozialversicherung (2026, September 08). Heilmittel-Evaluierungs-Kommission (HEK). Available online: https:\/\/www.sozialversicherung.at\/cdscontent\/?contentid=10007.904650&portal=svportal."},{"key":"ref_39","unstructured":"Global Legal Insights (2026, September 08). Austria\u2014ARCHIVED CHAPTER Pricing & Reimbursement Laws and Regulations. Available online: https:\/\/www.globallegalinsights.com\/practice-areas\/pharmaceutical-pricing-and-reimbursement-laws-and-regulations\/austria\/."},{"key":"ref_40","unstructured":"(2026, September 08). Pharmaceutical Pricing and Reimbursment Information (PPRI). PPRI Pharma Brief: \u00d6sterreich. Available online: https:\/\/ppri.goeg.at\/system\/files\/inline-files\/PPRI_Pharma_Brief_AT_2026.pdf."},{"key":"ref_41","unstructured":"(2026, July 31). Mittelstand Global Exportinitiative Gesundheitswissenschaft. Die Erstattung von Arzneimitteln in \u00d6sterreich. Exportinitiative Gesundheitswirtschaft [Internet]. Available online: https:\/\/www.gtai.de\/resource\/blob\/1867826\/c75fb386bcdcd5885dda48c6d09a25f6\/20250130_Infosheet_%C3%96sterreich_WEB.pdf."},{"key":"ref_42","unstructured":"Larcher, D., and Reisinger, C. (2026, July 31). Pricing & Reimbursement Laws and Regulations 2024\u2014Austria. Global Legal Insights [Internet]. Available online: https:\/\/www.globallegalinsights.com\/practice-areas\/pricing-reimbursement-laws-and-regulations\/austria."},{"key":"ref_43","unstructured":"(2026, July 15). Rechtsinformationssystem des Bundes. Bundesrecht Konsolidiert: Gesamte Rechtsvorschrift f\u00fcr Krankenanstalten-und Kuranstaltengesetz. Available online: https:\/\/www.ris.bka.gv.at\/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10010285."},{"key":"ref_44","unstructured":"(2026, September 08). Rijksinstituut Voor Ziekte-en Invaliditeitsverzekering (RIZIV). Rijksinstituut Voor Ziekte-en Invaliditeitsverzekering, Available online: https:\/\/www.riziv.fgov.be\/nl."},{"key":"ref_45","unstructured":"(2026, September 08). \u041d\u0430\u0446\u0438o\u043d\u0430\u043b\u0435\u043d \u0421\u044a\u0432\u0435\u0442 \u043fo \u0426\u0435\u043d\u0438 \u0438 \u0420\u0435\u0438\u043c\u0431\u0443\u0440\u0441\u0438\u0440\u0430\u043d\u0435 \u043d\u0430 \u041b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u0438\u0442\u0435 \u041f\u0440o\u0434\u0443\u043a\u0442\u0438. \u041d\u0430\u0447\u0430\u043bo. Available online: https:\/\/ncpr.bg."},{"key":"ref_46","unstructured":"\u041d\u0430\u0446\u0438o\u043d\u0430\u043b\u043d\u0430 \u0417\u0434\u0440\u0430\u0432\u043doo\u0441\u0438\u0433\u0443\u0440\u0438\u0442\u0435\u043b\u043d\u0430 \u041a\u0430\u0441\u0430 (\u041d\u0417\u041e\u041a) (2026, September 08). \u041d\u0430\u0447\u0430\u043bo\u2014\u041d\u0430\u0446\u0438o\u043d\u0430\u043b\u043d\u0430 \u0417\u0434\u0440\u0430\u0432\u043doo\u0441\u0438\u0433\u0443\u0440\u0438\u0442\u0435\u043b\u043d\u0430 \u041a\u0430\u0441\u0430 (\u041d\u0417\u041e\u041a). Available online: https:\/\/www.nhif.bg\/."},{"key":"ref_47","unstructured":"(2026, September 08). Pharmaceutical Pricing and Reimbursement Information (PPRI). Bulgaria\u2014Recent and Planned Developments in Pharmaceutical Policies. Available online: https:\/\/ppri.goeg.at\/system\/files\/inline-files\/Bulgaria_Country_Poster_PPRI%20Lisbon_0.pdf."},{"key":"ref_48","unstructured":"GuideBG (2026, July 15). Bulgarian Pharmaceutical Market in 2024\/25. Available online: https:\/\/www.guidebg.com\/bulgarian-pharmaceutical-market-in-2024-25\/."},{"key":"ref_49","unstructured":"(2026, September 08). HALMED\u2014Agencija za Lijekove i Medicinske Proizvode. HALMED\u2014Agencija za Lijekove i Medicinske Proizvode. Available online: https:\/\/www.halmed.hr\/."},{"key":"ref_50","unstructured":"(2026, September 08). Hrvatski Zavod za Zdravstveno Osiguranje. Hrvatski Zavod za Zdravstveno Osiguranje: Naslovna. Available online: https:\/\/hzzo.hr\/."},{"key":"ref_51","unstructured":"(2026, September 07). O\u03c1\u03b3\u03b1\u03bd\u03b9\u03c3\u03bc\u03cc\u03c2 A\u03c3\u03c6\u03ac\u03bb\u03b9\u03c3\u03b7\u03c2 \u03a5\u03b3\u03b5\u03af\u03b1\u03c2 (OA\u03a5). \u0393\u03b5\u03bd\u03b9\u03ba\u03cc \u03a3\u03cd\u03c3\u03c4\u03b7\u03bc\u03b1 \u03a5\u03b3\u03b5\u03af\u03b1\u03c2 (\u0393\u03b5\u03a3\u03a5). Available online: https:\/\/www.gesy.org.cy."},{"key":"ref_52","unstructured":"(2026, September 08). \u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf \u03a5\u03b3\u03b5\u03af\u03b1\u03c2. \u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf \u03a5\u03b3\u03b5\u03af\u03b1\u03c2, Available online: https:\/\/www.moh.gov.gr\/."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/14737167.2023.2237684","article-title":"Implementing a Managed Entry Agreement Framework in Cyprus","volume":"23","author":"Pitsillidou","year":"2023","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_54","unstructured":"(2026, September 08). Pharmaceutical Pricing and Reimbursement Information (PPRI). PPRI Pharma Brief: Cyprus. Available online: https:\/\/ppri.goeg.at\/sites\/ppri.goeg.at\/files\/inline-files\/PPRI_Pharma_Brief_Cyprus_2021_final_bf.pdf."},{"key":"ref_55","unstructured":"(2026, September 08). St\u00e1tn\u00ed \u00dastav Pro Kontrolu L\u00e9\u010div. St\u00e1tn\u00ed \u00dastav Pro Kontrolu L\u00e9\u010div, Available online: https:\/\/sukl.gov.cz\/."},{"key":"ref_56","unstructured":"(2026, September 08). L\u00e6gemiddelstyrelsen\u2014Danish Medicines Agency. L\u00e6gemiddelstyrelsen Forside. Available online: https:\/\/laegemiddelstyrelsen.dk\/."},{"key":"ref_57","unstructured":"(2026, September 08). Medicinr\u00e5det. Available online: https:\/\/medicinraadet.dk\/."},{"key":"ref_58","unstructured":"(2026, September 08). Tervisekassa. Available online: https:\/\/tervisekassa.ee\/."},{"key":"ref_59","unstructured":"(2026, September 08). Ravimiamet. Available online: https:\/\/www.ravimiamet.ee\/."},{"key":"ref_60","unstructured":"(2026, September 08). Sotsiaalministeerium. Available online: https:\/\/www.sm.ee\/."},{"key":"ref_61","unstructured":"(2026, September 08). L\u00e4\u00e4kkeiden Hintalautakunta. Etusivu\u2014L\u00e4\u00e4kkeiden Hintalautakunta. Available online: https:\/\/www.hila.fi\/."},{"key":"ref_62","unstructured":"(2026, September 08). Fimea. Etusivu\u2014Fimea.fi\u2014Fimea. Available online: https:\/\/fimea.fi\/."},{"key":"ref_63","unstructured":"Terveydenhuollon Palveluvalikoimaneuvosto (2026, September 08). Etusivu\u2014Palveluvalikoimaneuvosto. Available online: https:\/\/palveluvalikoima.fi\/etusivu."},{"key":"ref_64","unstructured":"(2026, September 08). Kansallinen HTA-Koordinaatioyksikk\u00f6 FinCCHTA. FinCCHTA. Available online: https:\/\/fincchta.fi\/."},{"key":"ref_65","unstructured":"(2026, September 08). Haute Autorit\u00e9 de Sant\u00e9. Haute Autorit\u00e9 de Sant\u00e9\u2014HAS\u2014Professional. Available online: https:\/\/www.has-sante.fr\/."},{"key":"ref_66","unstructured":"(2026, September 08). Minist\u00e8re de la Sant\u00e9, de la Famille, de l\u2019Autonomie et des Personnes Handicap\u00e9es, Available online: https:\/\/sante.gouv.fr\/."},{"key":"ref_67","unstructured":"Minist\u00e8re de la Sant\u00e9, de la Famille, de l\u2019Autonomie et des Personnes Handicap\u00e9es (2026, September 08). Pr\u00e9sentation du Comit\u00e9 \u00c9conomique des Produits de Sant\u00e9 (CEPS), Available online: https:\/\/sante.gouv.fr\/ministere\/acteurs\/instances-rattachees\/comite-economique-des-produits-de-sante-ceps\/article\/presentation-du-comite-economique-des-produits-de-sante-ceps."},{"key":"ref_68","unstructured":"Union Nationale des Caisses D\u2019assurance Maladie (2026, September 08). La Gouvernance de l\u2019Assurance Maladie. Available online: https:\/\/www.assurance-maladie.ameli.fr\/qui-sommes-nous\/notre-fonctionnement\/gouvernance\/gouvernance-assurance-maladie."},{"key":"ref_69","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (2026, September 08). Accueil\u2014ANSM. Available online: https:\/\/ansm.sante.fr\/."},{"key":"ref_70","unstructured":"Global Legal Insights (2026, September 08). Pharmaceutical Pricing & Reimbursement Laws and Regulations 2026\u2014France. Available online: https:\/\/www.globallegalinsights.com\/practice-areas\/pharmaceutical-pricing-and-reimbursement-laws-and-regulations\/france\/."},{"key":"ref_71","unstructured":"Gemeinsamer Bundesausschuss (G-BA) (2026, September 08). Startseite\u2014Gemeinsamer Bundesausschuss. Available online: https:\/\/www.g-ba.de\/."},{"key":"ref_72","unstructured":"(2026, September 08). Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Available online: https:\/\/www.iqwig.de\/."},{"key":"ref_73","unstructured":"GKV Spitzenverband (2026, September 08). Startseite\u2014GKV-Spitzenverband. Available online: https:\/\/www.gkv-spitzenverband.de\/."},{"key":"ref_74","unstructured":"(2026, September 08). Pharmaceutical Pricing and Reimbursement Information (PPRI). Greece\u2014Pharmaceutical Pricing and Reimbursement Policies. Available online: https:\/\/ppri.goeg.at\/system\/files\/inline-files\/Greece_Pharmaceutical_pricing_and_reimbursement_policies_2024_0.pdf."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"George, P., Eleftheria, K., and Kostas, A. (2026). Strengthening health technology assessment in Greece: Industry-identified barriers and recommendations. Front. Public Health, 14.","DOI":"10.3389\/fpubh.2026.1790128"},{"key":"ref_76","unstructured":"(2026, September 08). Nemzeti Eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si Alapkezel\u0151. Nemzeti Eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si Alapkezel\u0151, Available online: https:\/\/www.neak.gov.hu\/."},{"key":"ref_77","unstructured":"(2026, September 08). Pharmaceutical Pricing and Reimbursement Information (PPRI). Hungary\u2014Pharmaceutical Pricing and Reimbursement Policies. Available online: https:\/\/ppri.goeg.at\/system\/files\/inline-files\/Hungary_Pharmaceutical_pricing_and_reimbursement_policies_2024_0.pdf."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kawalec, P., Tesar, T., Vostalova, L., Draganic, P., Manova, M., Savova, A., Petrova, G., Rugaja, Z., M\u00e4nnik, A., and Sowada, C. (2017). Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00892"},{"key":"ref_79","unstructured":"(2026, September 08). Lyfjastofnun. Available online: https:\/\/www.ima.is\/."},{"key":"ref_80","unstructured":"(2026, September 08). Landsp\u00edtali. Landspitali. Available online: https:\/\/island.is\/s\/landspitali."},{"key":"ref_81","unstructured":"Health Service Executive (2026, September 08). HSE Website\u2014Health Service Executive. Available online: https:\/\/www.hse.ie\/."},{"key":"ref_82","unstructured":"(2026, September 08). National Centre for Pharmacoeconomics Ireland. National Centre for Pharmacoeconomics Ireland. Available online: https:\/\/www.ncpe.ie\/."},{"key":"ref_83","unstructured":"Global Legal Insights (2026, September 08). Pharmaceutical Pricing & Reimbursement Laws and Regulations 2026\u2014Ireland. Available online: https:\/\/www.globallegalinsights.com\/practice-areas\/pharmaceutical-pricing-and-reimbursement-laws-and-regulations\/ireland\/."},{"key":"ref_84","unstructured":"(2026, September 08). Agenzia Italiana del Farmaco (AIFA), Available online: https:\/\/www.aifa.gov.it\/."},{"key":"ref_85","unstructured":"(2026, September 08). Nacion\u0101lais Vesel\u012bbas Dienests. S\u0101kumlapa|Nacion\u0101lais Vesel\u012bbas Dienests, Available online: https:\/\/www.vmnvd.gov.lv\/."},{"key":"ref_86","unstructured":"(2026, September 08). Z\u0101\u013cu Valsts A\u0123ent\u016bra, Available online: https:\/\/www.zva.gov.lv\/."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s43441-025-00769-z","article-title":"Beyond Reimbursement Status: Availability of Advanced Therapy Medicinal Products Across the European Union","volume":"59","author":"Samek","year":"2025","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_88","unstructured":"Pharmaceutical Pricing and Reimbursement Information (PPRI) (2026, September 08). Latvia\u2014Pharmaceutical Pricing and Reimbursement Policies in the Outpatient and Inpatient Sectors. Available online: https:\/\/ppri.goeg.at\/system\/files\/inline-files\/Latvia_Pharmaceutical_pricing_and_reimbursement_policies_2024_1.pdf."},{"key":"ref_89","unstructured":"(2026, September 08). Amt F\u00fcr Gesundheit. Available online: https:\/\/www.llv.li\/de\/landesverwaltung\/amt-fuer-gesundheit."},{"key":"ref_90","unstructured":"Liechtensteinische Landesverwaltung (2026, July 31). Leistungskataloge und Verg\u00fctungslisten. Liechtensteinische Landesverwaltung [Internet]. Available online: https:\/\/www.llv.li\/de\/privatpersonen\/gesundheit-vorsorge-und-pflege\/versicherung\/krankenversicherung\/leistungskataloge-und-verguetungslisten."},{"key":"ref_91","unstructured":"Liechtensteinische Landesverwaltung (2026, July 31). Vertragsspit\u00e4ler und Bewilligungsinhaber. Liechtensteinische Landesverwaltung [Internet]. Available online: https:\/\/www.llv.li\/de\/privatpersonen\/gesundheit-vorsorge-und-pflege\/behandlung-und-pflege\/vertragsspitaeler-und-bewilligungsinhaber."},{"key":"ref_92","unstructured":"(2026, September 08). Valstybin\u0117 Vaist\u0173 Kontrol\u0117s Tarnyba Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos. Available online: https:\/\/vvkt.lrv.lt\/."},{"key":"ref_93","unstructured":"(2026, September 08). Valstybin\u0117 Ligoni\u0173 Kasa Prie Sveikatos Apsaugos Ministerijos. Available online: https:\/\/ligoniukasa.lrv.lt\/lt\/."},{"key":"ref_94","unstructured":"(2026, September 08). Lietuvos Respublikos Sveikatos Apsaugos Ministerija. Available online: https:\/\/sam.lrv.lt\/."},{"key":"ref_95","unstructured":"Caisse Nationale de Sant\u00e9 (CNS) (2026, September 08). Assur\u00e9\u2014CNS\u2014Luxembourg. Available online: https:\/\/cns.public.lu\/."},{"key":"ref_96","unstructured":"(2026, September 08). Minist\u00e8re de l\u2019\u00c9conomie. Minist\u00e8re de l\u2019\u00c9conomie, Available online: https:\/\/meco.gouvernement.lu\/."},{"key":"ref_97","unstructured":"Caisse Nationale de Sant\u00e9 (CNS) (2026, July 15). Medicines. Available online: https:\/\/cns.public.lu\/en\/professionnels-sante\/dossiers-thematiques\/medicaments-et-dispositifs\/medicaments.html."},{"key":"ref_98","unstructured":"Chambre des D\u00e9put\u00e9s du Grand-Duch\u00e9 de Luxembourg (2026, July 15). No 8491. Chambre des D\u00e9put\u00e9s. Available online: https:\/\/wdocs-pub.chd.lu\/docs\/Dossiers_parlementaires\/8491\/20250515_Dep%C3%B4t.pdf."},{"key":"ref_99","unstructured":"(2026, September 08). Ministeru G\u0127as-Sa\u0127\u0127a, Available online: https:\/\/sahha.gov.mt\/."},{"key":"ref_100","unstructured":"Global Legal Insights (2026, September 08). Pharmaceutical Pricing & Reimbursement Laws and Regulations 2026\u2014Malta. Available online: https:\/\/www.globallegalinsights.com\/practice-areas\/pharmaceutical-pricing-and-reimbursement-laws-and-regulations\/malta\/."},{"key":"ref_101","unstructured":"(2026, September 08). Pharmaceutical Pricing and Reimbursement Information (PPRI). PPRI Pharma Brief: Malta. Available online: https:\/\/ppri.goeg.at\/system\/files\/inline-files\/PPRI_Pharma_Malta_Brief_final.pdf."},{"key":"ref_102","unstructured":"Direktoratet for Medisinske Produkter (2026, September 08). Forside\u2014Direktoratet for Medisinske Produkter. Available online: https:\/\/www.dmp.no\/."},{"key":"ref_103","unstructured":"Nye Metoder (2026, September 08). Information in English. Available online: https:\/\/www.nyemetoder.no\/en\/english."},{"key":"ref_104","unstructured":"(2026, September 08). Sykehusinnkjop. Forside\u2014Sykehusinnkj\u00f8p HF. Available online: https:\/\/www.sykehusinnkjop.no\/."},{"key":"ref_105","unstructured":"(2026, September 08). Agencja Oceny Technologii Medycznych i Taryfikacji Agencja Oceny Technologii Medycznych i Taryfikacji (AOTMiT), Available online: https:\/\/www.aotm.gov.pl\/."},{"key":"ref_106","unstructured":"(2026, September 08). Ministerstwo Zdrowia, Available online: https:\/\/www.gov.pl\/web\/zdrowie."},{"key":"ref_107","unstructured":"(2026, September 08). INFARMED\u2014Autoridade Nacional do Medicamento e Produtos de Sa\u00fade IP. Infarmed. Available online: https:\/\/www.infarmed.pt\/."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"861","DOI":"10.30968\/rbfhss.2022.133.0861","article-title":"Avalia\u00e7\u00e3o de Tecnologias de Sa\u00fade em Portugal: Pol\u00edticas de sa\u00fade, metodologias e desafios emergentes","volume":"13","author":"Caldeira","year":"2022","journal-title":"Rev. Bras. Farm\u00e1cia Hosp. Servi\u00e7os Sa\u00fade"},{"key":"ref_109","unstructured":"Presid\u00eancia do Conselho de Ministros (2026, July 15). Decreto-Lei n.\u00ba 118\/2026, de 17 de Junho. Available online: https:\/\/diariodarepublica.pt\/dr\/detalhe\/decreto-lei\/118-2026-1133485780."},{"key":"ref_110","unstructured":"(2026, September 08). Agen\u021bia Na\u021bional\u0103 a Medicamentului \u0219i a Dispozitivelor Medicale din Rom\u00e2nia. ANMDMR\u2014Agen\u021bia Na\u021bional\u0103 a Medicamentului \u0219i a Dispozitivelor Medicale din Rom\u00e2nia. Available online: https:\/\/www.anm.ro\/."},{"key":"ref_111","unstructured":"(2026, September 08). Ministerul S\u0103n\u0103t\u0103\u021bii. Available online: https:\/\/www.ms.ro\/ro\/."},{"key":"ref_112","unstructured":"Casa Na\u021bional\u0103 de Asigur\u0103ri de S\u0103n\u0103tate (2026, September 08). Casa Na\u021bional\u0103 de Asigur\u0103ri de S\u0103n\u0103tate\u2014Eficacitate \u0219i Accesibilitate Pentru S\u0103n\u0103tate. Available online: https:\/\/cnas.ro\/."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Negrila, C.D., Gherasie, L.-M., Armean, S.M., and Armean, P. (2026). From Legislative Harmonization to Real-World Access: A Scoping Review of Pharmaceutical Regulation and Access to Medicines in Romania. Healthcare, 14.","DOI":"10.3390\/healthcare14050688"},{"key":"ref_114","unstructured":"(2026, September 08). Zdravotn\u00edctve NNiphatv. NIHO\u2014N\u00e1rodn\u00fd In\u0161tit\u00fat Pre Hodnotu a Technol\u00f3gie v Zdravotn\u00edctve. Available online: https:\/\/www.niho.sk\/."},{"key":"ref_115","unstructured":"(2026, September 08). Ministerstvo Zdravotn\u00edctva Slovenskej Republiky, Available online: https:\/\/www.health.gov.sk\/Titulka."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vhri.2017.07.002","article-title":"Drug Policy in Slovakia","volume":"13","author":"Visnansky","year":"2017","journal-title":"Value Health Reg. Issues"},{"key":"ref_117","unstructured":"Organisation for Economic Co-Operation and Development (2026, July 31). European Observatory on Health Systems and Policies. Slovakia: Country Health Profile 2025. State of Health in the EU [Internet]. Available online: https:\/\/health.ec.europa.eu\/document\/download\/fe7cc01d-9f18-4343-af4e-dd6cd60ffc9f_en?filename=2025_chp_sk_english.pdf."},{"key":"ref_118","unstructured":"N\u00e1rodn\u00e1 Rada Slovenskej Republiky (NRSR) (2026, July 15). NRSR: Schv\u00e1lila Z\u00e1kon, Ktor\u00fdm sa Zriadi N\u00e1rodn\u00fd HTA In\u0161tit\u00fat. Available online: https:\/\/www.nrsr.sk\/web\/Default.aspx?MasterID=55772&sid=udalosti%2Fudalost."},{"key":"ref_119","unstructured":"(2026, September 08). Zavod za Zdravstveno Zavarovanje Slovenije. Available online: https:\/\/www.zzzs.si\/."},{"key":"ref_120","unstructured":"(2026, September 08). Javna Agencija Republike Slovenije za Zdravila in Medicinske Pripomo\u010dke (JAZMP). Available online: https:\/\/www.jazmp.si."},{"key":"ref_121","unstructured":"(2026, September 08). Pharmaceutical Pricing and Reimbursement Information (PPRI). Slovenia\u2014In- and Out-Patient System. Available online: https:\/\/ppri.goeg.at\/sites\/ppri.goeg.at\/files\/inline-files\/Slovenia.pdf."},{"key":"ref_122","unstructured":"(2026, September 08). Pharmaceutical Pricing and Reimbursement Information (PPRI). Slovenia\u2014Recent and Planned Developments in Pharmaceutical Policies 2025. Available online: https:\/\/ppri.goeg.at\/system\/files\/inline-files\/Slovenia_Country_Poster_PPRI%20Lisbon_0.pdf."},{"key":"ref_123","unstructured":"iMPACT HTA (2026, July 15). Country Vignette Slovenia. Available online: https:\/\/29fc9734-3e90-46b6-9e22-9a9705501c78.filesusr.com\/ugd\/e1a359_8e62b18c85c5454d80c583ecb82be044.pdf."},{"key":"ref_124","first-page":"19","article-title":"Access to innovative medicines in Slovenia: Dostopnost inovativnih zdravil v Sloveniji","volume":"16","year":"2023","journal-title":"Acta Med.-Biotech."},{"key":"ref_125","unstructured":"(2026, September 08). Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Available online: https:\/\/www.aemps.gob.es\/."},{"key":"ref_126","unstructured":"(2026, September 08). Ministerio de Sanidad. Ministerio de Sanidad. Available online: https:\/\/www.sanidad.gob.es\/."},{"key":"ref_127","unstructured":"(2026, September 08). Comisi\u00f3n Interministerial de Precios de los Medicamentos y Productos Sanitarios (CIPM). Available online: https:\/\/www.sanidad.gob.es\/en\/areas\/farmacia\/precios\/comisionInteministerial\/home.htm."},{"key":"ref_128","unstructured":"Global Legal Insights (2026, September 08). Pharmaceutical Pricing & Reimbursement Laws and Regulations 2026\u2014Spain. Available online: https:\/\/www.globallegalinsights.com\/practice-areas\/pharmaceutical-pricing-and-reimbursement-laws-and-regulations\/spain\/."},{"key":"ref_129","unstructured":"AELMHU, and Asociaci\u00f3n Espa\u00f1ola de Laboratorios de Medicamentos Hu\u00e9rfanos y Ultrahu\u00e9rfanos (2026, September 08). Analysis of the Therapeutic Positioning Reports 2013\u20132022. Available online: https:\/\/aelmhu.es\/wp-content\/uploads\/2022\/07\/TPR_2022_AELMHU_English.pdf."},{"key":"ref_130","unstructured":"Agencia Estatal Bolet\u00edn Oficial del Estado (2026, July 15). Real Decreto 415\/2026, de 27 de mayo, por el que se Regula la Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias. Available online: https:\/\/www.boe.es\/diario_boe\/txt.php?id=BOE-A-2026-11587."},{"key":"ref_131","unstructured":"(2026, September 08). Tandv\u00e5rds-och L\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). Tandv\u00e5rds- Och L\u00e4kemedelsf\u00f6rm\u00e5nsverket. Available online: https:\/\/www.tlv.se\/."},{"key":"ref_132","unstructured":"(2026, September 08). Regionernas Samverkansmodell F\u00f6r L\u00e4kemedel. Samverkanl\u00e4kemedel. Available online: https:\/\/samverkanlakemedel.se\/."},{"key":"ref_133","unstructured":"(2026, September 08). Zorginstituut Nederland. Available online: https:\/\/www.zorginstituutnederland.nl\/."},{"key":"ref_134","unstructured":"(2026, September 08). Ministerie van Volksgezondheid, Welzijn en Sport. Available online: https:\/\/www.rijksoverheid.nl\/ministeries\/ministerie-van-volksgezondheid-welzijn-en-sport."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1017\/S1744133120000237","article-title":"Broadening the application of health technology assessment in the Netherlands: A worthwhile destination but not an easy ride?","volume":"16","author":"Enzing","year":"2021","journal-title":"Health Econ. Policy Law"},{"key":"ref_136","unstructured":"Global Legal Insights (2026, September 08). Netherlands\u2014Archived Chapter Pricing & Reimbursement Laws and Regulations. Available online: https:\/\/www.globallegalinsights.com\/practice-areas\/pharmaceutical-pricing-and-reimbursement-laws-and-regulations\/netherlands\/."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v040.i04","article-title":"Analyzing and Visualizing State Sequences in R with TraMineR","volume":"40","author":"Gabadinho","year":"2011","journal-title":"J. Stat. Softw."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2307\/204500","article-title":"Optimal matching methods for historical sequences","volume":"16","author":"Abbott","year":"1986","journal-title":"J. Interdiscip. Hist."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/rssa.12125","article-title":"What matters in differences between life trajectories: A comparative review of sequence dissimilarity measures","volume":"179","author":"Studer","year":"2016","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/01621459.1963.10500845","article-title":"Hierarchical grouping to optimize an objective function","volume":"58","author":"Ward","year":"1963","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_141","first-page":"32","article-title":"A new method for non-parametric multivariate analysis of variance","volume":"26","author":"Anderson","year":"2001","journal-title":"Austral Ecol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1541-0420.2005.00440.x","article-title":"Distance-based tests for homogeneity of multivariate dispersions","volume":"62","author":"Anderson","year":"2006","journal-title":"Biometrics"},{"key":"ref_143","unstructured":"Eurostat (2026, April 15). Gross Domestic Product (GDP) and Main Components per Capita\u2014Annual Data: Gross Domestic Product at Market Prices, Current Prices, Purchasing Power Standard (PPS, EU27 from 2020) per Capita, 2024 [nama_10_pc]. Available online: https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/nama_10_pc\/default\/table?lang=en."},{"key":"ref_144","unstructured":"Eurostat (2026, April 15). Health Care Expenditure by Financing Scheme: All Financing Schemes, Euro Per Inhabitant, Annual Data [hlth_sha11_hf]. Available online: https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/HLTH_SHA11_HF__custom_584545\/default\/table?lang=en."},{"key":"ref_145","unstructured":"European Commission European Health Digital Executive Agency, Tetra Tech, Gesundheit \u00d6sterreich, Beratungs, Gmbh, Vogler, S., Salcher-Konrad, M., and Habimana, K. (2026, July 31). Study on Best Practices in the Public Procurement of Medicines\u2014Final Report. Available online: https:\/\/op.europa.eu\/en\/publication-detail\/-\/publication\/ca856a7f-7c37-11ed-9887-01aa75ed71a1."},{"key":"ref_146","unstructured":"(2026, July 15). Autoridade Nacional do Medicamento e Produtos de Sa\u00fade I.P. (Infarmed). Health Technology Assessment. Available online: https:\/\/www.infarmed.pt\/web\/infarmed\/entidades\/medicamentos-uso-humano\/avaliacao-tecnologias-de-saude."},{"key":"ref_147","unstructured":"Public Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP) (2026, July 15). Pricing of Medicinal Products. Available online: https:\/\/www.jazmp.si\/en\/human-medicines\/pricing-of-medicinal-products\/."},{"key":"ref_148","unstructured":"Gemeinsamer Bundesausschuss (G-BA) (2026, July 15). Verfahrensordnung des Gemeinsamen Bundesausschusses, Stand: 8. April 2026. Available online: https:\/\/www.g-ba.de\/downloads\/62-492-4105\/VerfO_2025-11-20_iK_2026-04-08.pdf."},{"key":"ref_149","unstructured":"National Centre for Pharmacoeconomics (NCPE) (2026, July 15). Submission Process Flowchart. Available online: https:\/\/www.ncpe.ie\/submission-process\/process-flochart\/."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Wang, T., and McAuslane, N. (2025). Ensuring the Efficiency and Effectiveness of Joint Clinical Assessment in National HTA Decision-Making: Insights from the 2024 CIRS Multi-Stakeholder Workshop. J. Mark. Access Health Policy, 13.","DOI":"10.3390\/jmahp13010009"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"101009","DOI":"10.1016\/j.hlpt.2025.101009","article-title":"Diverse structures and methods of national health technology assessment organizations: A scoping review","volume":"14","author":"Migliavaca","year":"2025","journal-title":"Health Policy Technol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Wang, T., McAuslane, N., Liberti, L., Gardarsdottir, H., Goettsch, W., and Leufkens, H. (2020). Companies\u2019 Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.594549"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.healthpol.2019.08.008","article-title":"Shedding light on the HTA consultancy market: Insights from Poland","volume":"123","author":"King","year":"2019","journal-title":"Health Policy"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e240052","DOI":"10.57264\/cer-2024-0052","article-title":"EU HTA Joint Clinical Assessment: Are patients with rare disease going to lose out?","volume":"13","author":"Castanon","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Kloc, K., Toumi, M., Lukomska, E., Kowalska, M., Tyrala-Chowaniec, I., Simoens, S., Wasem, J., Boyer, L., Dussart, C., and Auquier, P. (2026). Joint Clinical Assessment in the EU HTA Regulation-Would Drugs Supported by Single-Arm Trials Fit Under Evaluation?. J. Mark. Access Health Policy, 14.","DOI":"10.3390\/jmahp14020036"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Desmet, T., Brijs, M., Vanderdonck, F., Tops, S., Simoens, S., and Huys, I. (2024). Implementing the EU HTA regulation: Insights from semi-structured interviews on patient expectations, Belgian and European institutional perspectives, and industry outlooks. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1369508"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Xander, N.S.H., Rutten-van M\u00f6lken, M.P.M.H., Bertin, L., Miljkovi\u0107, N., and Uyl-de Groot, C.A. (2026). Legal implications of joint clinical assessments under the EU HTA regulation. Health Econ. Policy Law, 1\u201313.","DOI":"10.1017\/S1744133126100413"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1017\/S0266462324002058","article-title":"PP32 Health Technology Assessment Regulation in Europe: Implications For A National Authority","volume":"40","author":"Usher","year":"2024","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2019.07.017","article-title":"Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations","volume":"23","author":"Vreman","year":"2020","journal-title":"Value Health"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1017\/S026646232610364X","article-title":"Implementing the EU HTA regulation and joint clinical assessment: A multi-stakeholder perspective from Italy","volume":"42","author":"Meregaglia","year":"2026","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_161","unstructured":"Rijksinstituut Voor Ziekte-en Invaliditeitsverzekering (RIZIV) (2026, July 15). Aanvraag tot Opname in de Terugbetaling van een Specialiteit in Klasse 1, Available online: http:\/\/www.riziv.fgov.be\/SiteCollectionDocuments\/richtlijnen_specialiteit_klasse1.doc."},{"key":"ref_162","unstructured":"Gemeinsamer Bundesausschuss (G-BA) (2026, July 15). Formulare und Vorgaben zum Download\u2014Anlagen zum 5. Kapitel der Verfahrensordnung (Engl. Forms and Templates for Download\u2014Attachments to Chapter 5 of the Rules of Procedure). Available online: https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/informationen-fuer-unternehmen\/formulare-und-vorgaben\/."},{"key":"ref_163","unstructured":"State Agency of Medicines Republic of Latvia (2026, July 15). Cost-Effectiveness Assessment, Available online: https:\/\/www.zva.gov.lv\/en\/industry\/marketing-authorisation-holders\/cost-effectivenes-assessment."}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/3\/55\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:16:25Z","timestamp":1789636585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/3\/55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":163,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jmahp14030055"],"URL":"https:\/\/doi.org\/10.3390\/jmahp14030055","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}